D3.137 - Effectiveness of Dupilumab in improving Quality of Life in patients with "steroid-resistant" asthma and severe atopic dermatitis

Asthma is a heterogeneous disease, not only in its clinical expression and course but also in its response to treatment with deleterious effects on Quality of Life (QoL).

The aim of the present study was to evaluate the effectiveness of Dupilumab treatment in improving QoL in patients with severe persistent allergic asthma (SPAA) resistant to steroid associated with atopic dermatitis (AD).

22 patients, aged 18-50 with SPAA and AD who met the following inclusion criteria: ≥ 2 severe asthma exacerbations requiring oral corticosteroids while receiving high dose ICS (≥ 1600 ∪g beclomethazone daily); baseline serum total IgE level of 100-2000 IU/ml; positive skin prick to at least one perennial allergen; FEV₁ between 45% and 60% of predicted. Dupilumab were administered (600mg loading dose followed by 300 mg maintenance/2weeks for minimum 6 months ( janauary 2022-december2024). Assessments were taken at week 24 on a 4 point scale (0=no symtoms and 3=severe symptoms). Eczema Area and severity Index (EASI) score was also evaluated. Data was also collected to evaluate patient's satisfaction with Dupilumab during the six months treatment. 

Reductions were seen in the asthmatic scores: wheezing (P=0.002) and breathlessness scores (P=0.0002). Dupilumab significanly reduced scores from baseline in nasal symptoms (P<0.001). The EASI improvement at visit 180 were 90%. Dupilumab was perceived as better by 98% of patients compared at baseline.

Dupilumab showed effective symptom control in SPAA. Symptoms of comorbidities such as thinitis and AD were decreased.